# First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

> **NCT05940571** · PHASE1 · COMPLETED · sponsor: **Medibiofarma S.L.** · enrollment: 16 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** MBF-362

## Key facts

- **NCT ID:** NCT05940571
- **Lead sponsor:** Medibiofarma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-24
- **Primary completion:** 2024-11-26
- **Final completion:** 2025-01-16
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940571, "First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05940571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*